Evidence map›Paper›PMID 33922888›Full record

ReviewInternational journal of molecular sciences2021

Beyond Dopamine Receptor Antagonism: New Targets for Schizophrenia Treatment and Prevention.

Felipe V Gomes, Anthony A Grace

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 2 pooled it
3.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 56 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Review
  6. Modulatory effects ofNutrition research and practice · 2026
    Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Felipe V GomesDepartment of Pharmacology, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto 01000-000, Brazil.ORCID 0000-0003-1033-1850
Anthony A GraceDepartments of Neuroscience, Psychiatry and Psychology, University of Pittsburgh, Pittsburgh, PA 15260, USA.ORCID 0000-0003-1864-5504
Universidade de São Paulo · BRUniversity of Pittsburgh · US

Funding

Gating of Information Flow Within the Nucleus Accumbens (Supplement)R01MH057440 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ANTHONY A GRACE · 1997 to 2026
$7.2M
FAPESP 2018/17597-3NIH HHS MH57440NIMH NIH HHS R01 MH057440
6 · The paper itself

Abstract

Treatment of schizophrenia (SCZ) historically relies on the use of antipsychotic drugs to treat psychosis, with all of the currently available antipsychotics acting through the antagonism of dopamine D2 receptors. Although antipsychotics reduce psychotic symptoms in many patients, they induce numerous undesirable effects and are not effective against negative and cognitive symptoms. These highlight the need to develop new drugs to treat SCZ. An advanced understanding of the circuitry of SCZ has pointed to pathological origins in the excitation/inhibition balance in regions such as the hippocampus, and restoring function in this region, particularly as a means to compensate for parvalbumin (PV) interneuron loss and resultant hippocampal hyperactivity, may be a more efficacious approach to relieve a broad range of SCZ symptoms. Other targets, such as cholinergic receptors and the trace amine-associated receptor 1 (TAAR1), have also shown some promise for the treatment of SCZ. Importantly, assessing efficacy of novel compounds must take into consideration treatment history of the patient, as preclinical studies suggest prior antipsychotic treatment may interfere with the efficacy of these novel agents. However, while novel therapeutic targets may be more effective in treating SCZ, a more effective approach would be to prevent the transition to SCZ in susceptible individuals. A focus on stress, which has been shown to be a predisposing factor in risk for SCZ, is a possible avenue that has shown promise in preclinical studies. Therefore, therapeutic approaches based on our current understanding of the circuitry of SCZ and its etiology are likely to enable development of more effective therapeutic interventions for this complex disorder.

Indexed as

AnimalsAntipsychotic AgentsD-Amino-Acid OxidaseDopamine Antagonistsgamma-Aminobutyric AcidGlutamic AcidHumansMolecular Targeted TherapyReceptors, CholinergicReceptors, G-Protein-CoupledSchizophreniaSodium BenzoateTrace Amine-Associated ReceptorsAntipsychotic AgentsD-Amino-Acid OxidaseDAO protein, humanDopamine Antagonistsgamma-Aminobutyric AcidGlutamic AcidReceptors, CholinergicReceptors, G-Protein-CoupledSodium BenzoateTrace Amine-Associated Receptorsantipsychoticsdopamineglutamatehippocampusparvalbuminpsychosisstress

Identifiers

PMID33922888
PMCPMC8123139
OpenAlexW3159231782

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.